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Background: Particulate carriers are necessary to control the release of endostar and   prolong its 
circulation in vivo. The purpose of this study was to identify a suitable carrier for the   capsulation 
and delivery of endostar.
Methods: We prepared a series of poly (DL-lactide-co-glycolide) (PLGA) and poly (ethylene 
glycol) (PEG)-modified PLGA (PEG-PLGA) particulate carriers, and then characterized them 
according to their ability to prolong the circulation of endostar, their physicochemical properties, 
endostar-loading content, and in vitro and in vivo particulate carrier release profiles.
Results: All the particulate carriers had spherical core shell structures. The PEG-PLGA   material 
and nanosize range appeared to enable the carriers to encapsulate more endostar, release endostar 
faster in vitro, and accumulate more endostar in vivo. The drug loading capacity of PEG-PLGA 
and PLGA nanoparticles was 8.03% ± 3.41% and 3.27% ± 5.26%, respectively, and for PEG-
PLGA and PLGA microspheres was 15.32% ± 5.61% and 9.21% ± 4.73%. The cumulative 
amount of endostar released from the carriers in phosphate-buffered saline over 21 days was 
23.79%, 20.45%, 15.13%, and 10.41%, respectively. Moreover, the terminal elimination half-
life of endostar in the rabbit was 26.91 ± 7.93 hours and 9.32 ± 5.53 hours in the PEG-PLGA 
group and the PLGA nanoparticle group. Peak endostar concentration was reached at day 7 in 
the group treated with subcutaneous injection of PEG-PLGA microspheres and at day 14 in 
the group receiving subcutaneous injection of PLGA microspheres. Endostar was detectable 
in vivo in both groups after injection of the particulate carriers.
Conclusion: PEG-PLGA nanoparticles might be better than other nanoparticulate carriers for 
encapsulation and distribution of endostar.
Keywords: poly(DL-lactide-co-glycolide), nanoparticle, microsphere, endostar, peptide 
delivery
Introduction
Endostar, a novel recombinant human endostatin, has been approved by the Chinese 
State Food And Drug Administration for the treatment of nonsmall cell lung cancer. 
Endostar has a broad spectrum of activity against solid tumors, by inhibiting endothelial 
cell proliferation, migration, and vessel formation.1–4 Despite its apparent therapeutic 
value, the biological half-life of endostar, like most other protein drugs, is short because 
of its rapid metabolism. Multiple injections of endostar at a high dose (7.5 mg/m2/day 
in the first 2 weeks of a 3-week treatment cycle), in order to maintain therapeutic levels, 
are still associated with fluctuating plasma endostar concentrations.5,6 It is expected 
that a long-acting formulation of endostar would provide stable antitumor activity and 
result in fewer injection-related complications.7International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Several attempts have been made to generate long-acting 
forms of endostatin, including alteration of the   molecule 
to increase its stability, direct poly(ethylene glycol) (PEG) 
  modification of the peptide, and other approaches.8   Mutagenesis 
and modification of the molecule is difficult because the 
bioactivity and efficacy of the peptide must be maintained, 
and integrity of multiple active sites and   conformation must 
be preserved. Recently, endostar-loaded microspheres and 
PEG-modified poly(DL-lactide-  co-glycolide) (PEG-PLGA) 
nanoparticles were prepared, with higher acid resistance and 
isoelectric point, and more   stability of endostar resulting from 
an additional nine amino acid sequence at the N terminus.9–12 
In addition, particulate   carriers represent new approaches to 
improving the pharmacodynamic properties of therapeutic pep-
tides, in that they can encapsulate and deliver drugs, and hydro-
lyze in an aqueous environment (hydrolytic degradation or 
  biodegradation) in a stable manner.13 Unlike other approaches, 
such as mutagenesis, direct PEGylation, and fusion to carrier 
proteins, particulate carriers have not been shown to change the 
amino acid sequence of any of the proteins involved.
The purpose of this study was to identify a suitable car-
rier for encapsulation and delivery of endostar. Because the 
physicochemical and biological properties of peptide drugs are 
different from those of other agents, including molecular size, 
biological half-life, conformation stability, physicochemical 
stability, and bioavailability, the design and preparation of these 
carriers is different. Liposomes, microspheres, and nanopar-
ticles are mostly used for peptide drug delivery.11 The structure, 
charge, solubility, and other properties, including the liposomes 
used for the different peptides vary and the formulation methods 
and materials are different.14 Moreover, liposomes are used 
more often for encapsulation of lipid-soluble medicines because 
of their fat solubility. Therefore, we prepared endostar-loaded 
nanoparticles and microspheres, and assessed their ability to 
prolong the circulation time of endostar.
Materials and methods
Materials
Endostar 5 mg/mL was obtained from Shandong Simcere 
Medgenn BioPharmaceutical Co Ltd (Yantai, China). PLGA 
(lactide:glycolide ratio 50:50, molecular weight 45 kDa) and 
PEG-PLGA (PEG molecular weight 2 kDa and PLGA molecu-
lar weight 45 kDa) were purchased from Shandong Institute of 
Medical Instruments (Shandong, China).12 PEG and PLGA are 
nontoxic, nonimmunogenic, and biodegradable, with the poten-
tial for controlled release of injected drugs and site-specific 
drug delivery.15,16 Polyvinyl alcohol (PVA, molecular weight 
13–23 kDa) and the primary antibodies for endostatin were 
purchased from Sigma-Aldrich (St Louis, MO) and Santa Cruz 
Biotechnology (Santa Cruz, CA), respectively. All other chemi-
cals used were of analytical grade. The apparatus, including 
transmission electron microscopy (Philips, the Netherlands), 
microscopy (Jiangnan Optical-Electrical Co Ltd, Nanjing, 
China), photon correlation spectroscopy (Malvern, Worcester-
shire, UK), ultraviolet spectrophotometry (Spectrum China Ltd, 
Shanghai, China), low-temperature ultracentrifugation (Hitachi, 
Japan), and enzyme-linked immunosorbent assay (Bio-Tek, 
Winooski, VT) were used. New Zealand rabbits (2–3 kg) were 
purchased from the Animal Center of Shandong University, 
China. All experiments performed with animals were approved 
by the ethics committee of Shandong University.
endostar-loaded PLgA and Peg-PLgA 
nanoparticles and microspheres
The PLGA and PEG-PLGA nanoparticles were prepared by 
a double emulsion (mixing solvent) as described in previ-
ous studies.12,17,18 This preparation technique was adapted to 
obtain nanoparticles and microspheres. Briefly, the first emul-
sion (o/w) was formed between a dichloromethane solution 
of PLGA or PEG-PLGA 5 mg/mL and endostar (0.05 mL, 
5 mg/mL) by high-speed shearing (2800 rpm for 60 seconds). 
Subsequently, a volume of 2 mL of 0.1% (w/v) PVA was 
added into this primary w/o emulsion to obtain the double 
emulsion (w/o/w) by high-speed shearing (25,000 rpm for 
60 seconds). The solvent was evaporated in 10 mL of   aqueous 
solution (0.1%, PVA) by gentle magnetic stirring (1000 rpm) 
at room temperature. The nanoparticles were recovered by 
centrifugation (40,000 rpm for 40 minutes), and washed three 
times in phosphate-buffered saline.
The PLGA and PEG-PLGA microspheres were also 
prepared by a double emulsion method, which was slightly 
different from that used to create the nanoparticles.11 The pri-
mary w/o emulsion was emulsified at 400 rpm for 30 seconds, 
added to 50 mL of aqueous solution containing 0.1% PVA, 
and stirred at 900 rpm for 4 hours at room temperature to 
evaporate the organic solvents. The microspheres were col-
lected by centrifugation at 5000 rpm for 3 minutes, washed 
three times, and freeze-dried.
Physicochemical characterization
The entrapment efficiency of particulate carriers was assayed 
using a direct method. After dissolving the lyophilized nano-
spheres or microspheres in 0.05 N NaOH and 1% sodium 
dodecyl sulfate, the endostar content was estimated using the 
micro bicinchoninic acid protein assay, which was validated 
using purified endostar.12,19 The lower limit of detection was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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0.005 µg/mL. No interference with PEG-PLGA, PLGA, or 
the stabilizers was observed. The drug-loading capacity and 
entrapment efficiency were calculated as follows:
Endostar loading capacity (%) = Mendostar/Mendostar–loaded particulate carriers   
             × 100
         E E   ( % )   = Mendostar/Mendostar devoted × 100
where EE is entrapment efficiency, Mendostar is the amount 
of drug in the nanoparticles or microspheres (Mendostar = 
C × V , C is   concentration in the supernatant, V is volume), 
Mendostar–loaded particulate carriers is the amount of nanoparticles or 
microspheres containing endostar, and Mendostar devoted is the 
initial amount of endostar.
Morphology of the nanoparticles was observed by 
  transmission electron microscopy, and particle size 
  distribution (mean diameter and polydispersity index) was 
determined by photon correlation spectroscopy. The size 
of the microspheres was determined using a microscope 
whereby 200 particles were counted to calculate the average 
diameter and percentage distribution of the microspheres.12
The presence of residual PVA on the surface of the particles 
was determined by both direct and indirect methods.20 The 
nanoparticles or microspheres were digested in 0.05 N NaOH 
and 1% sodium dodecyl sulfate. The solution obtained was then 
neutralized and analyzed for PVA content using the colorimet-
ric method.21 Residual PVA was also calculated according to 
the difference between the total amount used and the amount 
present in the supernatant during the washing steps. The average 
of the results obtained by the two methods was used.
release studies in  
phosphate-buffered saline
The nanoparticles or microspheres were also evaluated for 
their in vitro release characteristics using the horizontal shaker 
method.22 Endostar-loaded nanoparticles or microspheres 
were suspended in phosphate-buffered saline (pH 7.4, 0.01% 
sodium azide, 0.02% Tween80) in an Eppendorf dialysis tube, 
and stirred at 37°C ± 0.5°C and 100 rpm. At appropriate inter-
vals, we centrifuged the suspension, collected the supernatant, 
and added fresh phosphate-buffered saline dialysis buffer to 
the tube. The amount of endostar in the supernatants was 
determined using the micro bicinchoninic acid protein assay. 
Subsequently, the endostar release profiles were expressed in 
terms of cumulative protein release versus time.
In vivo release studies
The in vivo evaluation was performed using 30 male New 
Zealand rabbits, which were randomly divided into six 
groups and housed individually in a room at constant ambient 
  temperature and humidity. After an overnight fast, a bolus of 
endostar, endostar-loaded PLGA, or PEG-PLGA nanoparti-
cles containing endostar 90 mg/m2 was administered through 
the aural vein. In the other three groups, the same amount of 
endostar or endostar-loaded PLGA and PEG-PLGA micro-
spheres was given subcutaneously at the back of the neck. 
Blood samples were collected from the aural vein at a series 
of time intervals. The endostar concentration in plasma was 
determined using an enzyme-linked immunosorbent assay, 
which was validated using purified recombinant human 
endostatin with a detection limit of 0.002–0.5 µg/mL.
Amount of endostar in different  
tissues in vivo
The amount of endostar in the different tissues was detected 
by Western blot assay using a polyclonal antiendostatin 
antibody for investigating clearance efficacy in the rabbit.12,23 
Fifteen New Zealand rabbits, divided into three groups, were 
given the same dose of endostar, endostar-loaded PEG-
PLGA, or PLGA nanoparticles at 180 mg/m2. Tissue samples 
of liver, spleen, and lung were collected, weighed, and 
homogenated when the rabbits were sacrificed. The amount 
of endostar was determined by Western blot assay.
statistical analysis
All experiments were performed in triplicate, and data are 
shown as means ± standard deviation. The Student’s t-test 
was used to compare the treatment groups. P , 0.05 was 
considered to be statistically significant in all cases. The 
pharmacokinetics of endostar distribution were calculated 
using the DAS 2.0 program.23
Results
Physicochemical characterization
The endostar-loaded nanoparticles and microspheres were 
found to have a spherical core shell structure with a rela-
tively smooth surface. Although the size of the PEG-PLGA 
nanoparticles was similar to that of the PLGA nanoparticles 
(147.32 ± 31.93 nm vs 127.31 ± 26.18 nm, respectively, 
P . 0.05), the loading capacity and encapsulation efficiency 
was greater than for the PLGA nanoparticles (8.03% ± 
1.21% vs 3.27% ± 1.36%, P , 0.05). The size of the PEG-
PLGA nanoparticles was smaller than that of the PLGA 
  microspheres (147.32 ± 31.93 nm vs 27.45 ± 4.26 µm, 
P , 0.01), but there was no significant   difference between 
the PEG-PLGA nanoparticles and PLGA microspheres with 
regard to their loading capacity and encapsulation efficiency International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(8.03% ± 1.21% vs 9.21% ± 1.73%, P . 0.05). The residual 
PVA content of the PEG-PLGA nanoparticles was negli-
gible compared with that on the PLGA nanoparticle surface 
(0.6% ± 1.1% vs 6.3% ± 2.5%, P , 0.05). The amount of 
PVA on the PEG-PLGA microspheres was also less than that 
of the PLGA microspheres (0.3% ± 0.6% vs 3.2% ± 1.9%, 
P , 0.05). The particle size, loading capacity, encapsulation 
efficiency, PVA content, zeta potential, and polydispersity 
index of the particulate carriers are shown in Table 1.
release studies in  
phosphate-buffered saline
Endostar was released more rapidly from the nanoparticles 
than the microspheres, and the release speed from the 
PEG-PLGA nanoparticles was higher than that from the 
PLGA nanoparticles from the third release day onwards. 
The PEG-PLGA nanoparticles released more encapsulated 
endostar over the same time period. Endostar release from the 
endostar-loaded nanoparticles and microspheres (pH 7.04) 
in vitro was biphasic, with an initial abrupt release, followed 
by more sustained release (Figure 1). In the initial burst 
release, a significant amount of endostar was released within 
24 hours (9.27% for the PEG-PLGA nanoparticles, 10.56% 
for the PLGA nanoparticles, 5.02% for the PEG-PLGA 
microspheres, and 6.67% for the PLGA microspheres). 
  Subsequently, the endostar displayed a sustained release 
  profile. Cumulative endostar release over 21 days was 
24.15% for the PEG-PLGA nanoparticles, 20.31% for the 
PLGA nanoparticles, 14.35% for the PEG-PLGA micro-
spheres, and 10.32% for the PLGA microspheres.
release studies in vivo
Endostar concentrations in rat plasma in the PEG-PLGA 
nanoparticle-treated group could be maintained at high levels. 
Although the concentration of endostar in blood 10 minutes 
after intravenous administration in the endostar group was 
about four times that in the PEG-PLGA nanoparticle group, it 
was quickly removed from the circulation in the endostar only 
group, with a terminal elimination half-life of 2.72 ± 1.43 hours. 
While the endostar-loaded PEG-PLGA and PLGA nanopar-
ticles exhibited markedly delayed blood clearance, the elimina-
tion half-life of endostar was 26.93 ± 7.93 hours and 9.35 ± 
5.51 hours, respectively (P , 0.05). The areas under the curve 
for endostar in the PEG-PLGA, PLGA nanoparticle, and endo-
star groups were 69821.95 ± 6219.84 µg/L*hour, 15238.77 ± 
5916.18 µg/L*hour, and 23396.31 ± 7951.65 µg/L*hour, 
respectively. Mean plasma concentrations for the endostar 
and endostar-loaded nanoparticles in rabbits are shown in 
Figure 2. The endostar-loaded microspheres also showed 
a sustained release profile whereby the peak concentration 
was reached on day 7 for the PEG-PLGA microspheres and 
on day 14 for the PLGA microspheres, and was maintained 
until day 27 (Figure 3). The peak concentration of endostar 
in the PEG-PLGA microsphere group was higher than that 
in the PLGA microsphere group (0.3974 ± 0.0316 µg/mL vs 
0.3015 ± 0.0276 µg/mL, P , 0.05).
Amount of endostar in different  
tissues in vivo
The amount of endostar in different tissues in the PEG-
PLGA nanoparticle group was greater than in the PLGA or 
Table 1 Physicochemical characteristics of the nanoparticles and microspheres
Formulation Particle size Loading (%) EE (%) PVA content (%) Zeta potential (mV) PDI
Peg-PLgA nanoparticles (nm) 147.32 ± 31.93   8.03 ± 1.21 75.97 ± 8.67 0.6 ± 1.1 -16.2 ± 0.3 0.39 ± 0.15
PLgA nanoparticles (nm) 127.31 ± 26.18   3.27 ± 1.36* 65.45 ± 9.62* 6.3 ± 2.5* -33.3 ± 0.2 0.31 ± 0.18
Peg-PLgA microspheres (µm)   45.79 ± 6.87* 15.32 ± 1.21* 91.84 ± 3.29* 0.3 ± 0.6 -25.1 ± 0.5 0.46 ± 0.19
PLgA microspheres (µm)   27.45 ± 4.26*   9.21 ± 1.73 82.74 ± 5.67 3.2 ± 1.9* -57.9 ± 0.6 0.73 ± 0.22
Note: *Significantly different from PEG-PLGA nanoparticles (P , 0.05).
Abbreviations:  EE,  entrapment  efficiency;  PLGA,  poly(DL-lactide-co-glycolide);  PEG-PLGA,  poly(ethylene  glycol)  modified  poly(DL-lactide-
  co-glycolide); PVA, polyvinyl alcohol; PDI, polydispersity index.
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%
0 10 20
Time (days)
C
u
m
u
l
a
t
i
v
e
 
r
e
l
e
a
s
e
30 40
PLGA nanoparticles PEG-PLGA nanoparticles
PLGA microsphere PEG-PLGA microsphere
Endostar
*
*
*
* *
*
* *
* *
* * *
* *
*
*
*
*
*
* *
* *
* *
* *
* * * *
*
*
Figure  1  release  profiles  of  endostar  from  PLGA  nanoparticles,  PEG-PLGA 
nanoparticles, and PLgA and Peg-PLgA microspheres in phosphate-buffered saline. 
The error bars represent means ± standard deviation. The dissolution of endostar 
with a 25% concentration is also described.
Note: *Significantly different from PEG-PLGA nanoparticles (P , 0.05).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1539
endostar-loaded particulate carriers
microsphere groups. The amount of endostar was assayed 
by Western blot assay.12 Endostar was detectable only in the 
endostar-containing PEG-PLGA group and PLGA nanopar-
ticle group 5 hours after intravenous nanoparticle injection 
and was not detectable after subcutaneous microsphere 
injection (Figure 4). The relative tissue content of endostar 
(endostar: actin, %) in the endostar-loaded PEG-PLGA 
nanoparticle group was 200.5 ± 12.5 in the liver, 216.3 ± 15.2 
in the spleen, and 176.7 ± 8.6 in the lung, and was 109 ± 6.6, 
91 ± 5.7, and 67 ± 4.4, respectively, in the endostar-loaded 
PLGA nanoparticle group. Endostar was not detectable in 
the endostar or microsphere groups, even at day 7 after sub-
cutaneous injection.
Discussion
Both nanoparticles and microspheres can be developed 
using a double emulsion method, with similar release 
characteristics.11,12,24 However, there are still some differ-
ences between these two carriers. Table 1 shows higher 
encapsulation efficiencies of endostar in microspheres and 
PEG-PLGA particulate carriers, and less residual PVA con-
tent in PEG-PLGA particulate carriers. This may be attributed 
to the larger size and smaller surface area that enables the 
microspheres to encapsulate more drug and adsorb less PVA 
than the nanoparticles.25 The higher encapsulation rate for 
the endostar-loaded PEG-PLGA nanoparticles might result 
from the hydrophilic moiety on PEG. This hydrophilic moiety 
on the surface can more easily bind and encapsulate soluble 
endostar into particulate carriers. Less residual PVA on the 
surface of the PEG-PLGA nanoparticles or microspheres 
confirmed that PEG-PLGA was more hydrophilic than PLGA 
and hinders surface adsorption of PVA.20 Thus, the encapsu-
lation efficiency of PEG-PLGA nanoparticles was high.
The release speeds of the nanoparticles and microspheres 
were also different. PEG-PLGA or PLGA nanoparticulate 
carriers would hydrolyze in an aqueous environment (hydro-
lytic degradation or biodegradation), and release the encap-
sulated drug.13 The biodegradation rate of the particulate 
carriers was dependent on the hydrophilic/lipophilic ratio 
of the polymer and surface area. The more hydrophilic and 
the larger the surface area of the polymer, the more rapid 
its degradation.26 Thus, the presence of PEG had a positive 
effect on degradation of the nanoparticles and microspheres. 
As can be seen in Figure 2, higher total amounts of endo-
star were released from the PEG-PLGA nanoparticles and 
microspheres (Figure 2). The higher release effect observed 
for the nanoparticles as compared with the microspheres 
might be attributed to their larger surface area. Thus, different 
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  particulate carriers are chosen to control the release of drugs, 
modify their pharmacokinetics, enhance their anticancer 
effect, and decrease their toxicity.27–29 The PEG-PLGA nano-
particles encapsulated more endostar and released endostar 
more rapidly than the other three carriers.
Microsphere carriers were not suitable for loading 
  endostar. Most drug-loaded microspheres are too large in 
diameter to be administered intravenously, because large-
sized particulate carriers embolize easily in the blood ves-
sels,   triggering an opsonization effect in the immune system 
and they also have difficulty crossing endothelial barriers 
in   various hosts.30 Moreover, the effect of some medicines 
injected subcutaneously shows significant variation at dif-
ferent injection sites in different individuals, and this is 
attributed to variation in body response.31–33 Because of the 
presence of proteolytic enzymes, cellular infiltrates,   various 
cytokines, and pH gradients, subcutaneous conditions are 
complex in vivo. The release profile of endostar from the 
microspheres confirmed that the concentration levels of 
endostar were fluctuant and lower (Figure 3), and not detect-
able in tissues (data not shown).
However, the intravenously administered nanoparticles 
accumulated more easily in tissues, and the plasma concen-
tration of endostar was higher. Five hours after intravenous 
or subcutaneous injection, endostar was only detectable 
in the endostar-containing PEG-PLGA and PLGA nano-
particle groups, and not detectable in the endostar only or 
microsphere groups. The relative content of endostar in the 
endostar-loaded PEG-PLGA nanoparticle group was more 
than that in the endostar-loaded PLGA nanoparticle group. 
Furthermore, the elimination half-life of endostar in the 
PEG-PLGA nanoparticle group was longer than that in the 
PLGA nanoparticle or endostar groups (P , 0.05). These 
observations might result from PEG having a hydrophilic 
moiety which can prevent interactions with other cells and 
proteins,15,16 being cleared from the systemic circulation, and 
being transported in the lymphatic system. Studies have dem-
onstrated that nanoparticles with a PEG layer 100 nm thick are 
not easily engulfed by phagocytes.34,35 Moreover, PEG-PLGA 
nanoparticles might also accumulate easily in tumor tissue. 
As a result of the enhanced permeability of tumor endothe-
lium and lack of lymphatic drainage in tumor cells, there is 
increased extravasation and accumulation of drug in tumor 
vasculature and tumor tissue. In addition, endothelial cells in 
tumors are distinct from those in normal tissues, possessing 
wide fenestrations, ranging from 200 nm to 1.2 mm in size. 
The vascular pore size of the LS174T tumor, a human colon 
adenocarcinoma, may be as large as 400 nm.36 This large pore 
size allows passage of nanoparticles into the extravascular 
spaces, which is known as the “enhanced permeation and 
retention” effect. Thus, the PEG-PLGA nanoparticles accu-
mulate more easily in tumor tissue.
Conclusion
PEG-PLGA nanoparticles can maintain good concentrations 
of endostar in plasma and tissues, and show more promising 
characteristics than PLGA nanoparticles and microspheres. 
Although more investigations need to be done, PEG-PLGA 
nanoparticles seem to represent a suitable endostar carrier 
system. PEG-PLGA nanoparticles might also become novel 
carriers for other peptide medicines, providing new oppor-
tunities to control delivery of peptide drugs.
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